Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis

NCT06042647 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

10

Enrollment

NETWORK

Sponsor class

Conditions

Psoriasis Vulgaris

Interventions

DRUG: 0.01% Halobetasol
DRUG: 0.045% Tazarotene
DRUG: 0.05% Clobetasol Propionate

Sponsor

Dermatology Consulting Services, PLLC